Evidence map›Paper›PMID 41514630›Full record

ArticleCancers2025

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Juan Alban, R Christopher Bowen, David A Reichstein, Meredith McKean, Jose Lutzky, Ezekiel Weis, Richard D Carvajal, Susan Dulka, Brian G Morse, Marcus O Butler and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Juan AlbanRobert H. Lurie Comprehensive Cancer Center, Division of Hematology Oncology, Northwestern University, Chicago, IL 60616, USA.
R Christopher BowenDepartment of Ophthalmology, Northwestern University, Chicago, IL 60616, USA.ORCID 0000-0002-5836-1541
David A ReichsteinTennessee Retina, Nashville, TN 37203, USA.
Meredith McKeanSarah Cannon Research Institute, Nashville, TN 37203, USA.
Jose LutzkySylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
Ezekiel WeisDepartment of Ophthalmology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T5H 3V9, Canada.
Richard D CarvajalNorthwell Health Cancer Institute, New York, NY 11042, USA.
Susan DulkaDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Brian G MorseDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0001-6366-7222
Marcus O ButlerPrincess Margaret Cancer Centre, University Health Network, Departments of Medicine and Immunology, University of Toronto, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-9840-7057
Suthee RapisuwonDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Kevin B KimCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA.
Sanjay ChandrasekaranDivision of Hematology/Oncology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Allison Betof WarnerDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6422-2997
Jonathan S ZagerDepartments of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0002-6886-4468
Bartosz ChmielowskiDivision of Hematology and Medical Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, The University of California Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-2374-3320
Sapna P PatelDivision of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO 80045, USA.
Leonel Fernando Hernandez-AyaSylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
Zelia M CorreaSylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.ORCID 0000-0003-2946-3757
Leslie A FecherDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI 48109, USA.
Yana G NajjarUPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
Kamaneh MontazeriMassachusetts General Cancer Center, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-3693-5994
Alexander N ShoushtariDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-8065-4412
Asad JavedHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Dan S GombosMD Anderson Cancer Center, Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas, Houston, TX 77030, USA.ORCID 0000-0003-2867-6320
April K S SalamaDivision of Medical Oncology, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-8105-5374
Katy TsaiDepartment of Medicine, Division of Hematology/Oncology, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.
Frank H MillerDepartment of Radiology, Northwestern University Medical Center, Chicago, IL 60601, USA.
Nikhil KhushalaniDepartments of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Rino S SeedorSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Evan J LipsonDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0003-2976-0911
Sunil A ReddyDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Elizabeth BuchbinderDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Shailender BhatiaDivision of Hematology and Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-3816-2238
Anna PavlickDepartment of Medical Oncology, Weill Cornell Medicine, New York, NY 10021, USA.
Inderjit MehmiThe Angeles Clinic and Research Institute, Cedars Sinai Affiliate, Los Angeles, CA 90025, USA.ORCID 0000-0002-2253-2206
Thomas AabergRetina Specialists of Michigan, Foundation for Vision Research, Michigan State University College of Human Medicine, Grand Rapids, MI 49546, USA.
Alexandra P IkeguchiDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 73030, USA.ORCID 0000-0002-4448-9755
Ivana K KimMassachusetts Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
Scott D WalterRetina Consultants, Hartford, CT 06106, USA.ORCID 0000-0003-3492-4650
Arun D SinghDepartment of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH 44106, USA.ORCID 0000-0001-9411-0320
Ryan J SullivanMassachusetts General Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Jacob S ChoiRobert H. Lurie Comprehensive Cancer Center, Division of Hematology Oncology, Northwestern University, Chicago, IL 60616, USA.
Basil K WilliamsSylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
Marlana OrloffSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Prithvi MruthyunjayaByers Eye Institute, Stanford University School of Medicine, Watson Court, Palo Alto, CA 94303, USA.
Megan D SchollenbergerSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Namita GandhiDepartment of Radiology, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0002-6456-9453
J William HarbourDepartment of Ophthalmology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-1104-9809
Sunandana ChandraRobert H. Lurie Comprehensive Cancer Center, Division of Hematology Oncology, Northwestern University, Chicago, IL 60616, USA.ORCID 0000-0001-7936-5069

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

BACKGROUND/

objectivesUveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, most commonly to the liver, despite effective local treatment. In the absence of robust evidence, there are no standardized guidelines for post-treatment surveillance, resulting in wide variation in imaging modalities, frequency, and duration across physicians and institutions. This study aimed to develop expert consensus recommendations for surveillance strategies in patients with uveal melanoma.

methodsA modified Delphi method was conducted across three iterative survey rounds between September 2024 and February 2025 using an online platform. Panelists included medical oncologists, ocular oncologists, radiologists, and surgical oncologists from North America. A multidisciplinary steering committee developed statements addressing risk-based surveillance using both molecular and clinical prognostic factors, including gene expression profiling (GEP) and PRAME status. Consensus was defined a priori as ≥70% of panelists rating a statement 7-9 on a 9-point Likert scale.

resultsForty-nine experts were invited, and 41 completed at least one survey round. The panel represented 17 U.S. states, Washington, D.C., and two Canadian provinces. Twelve statements reached stable consensus, including recommendations for imaging modality, frequency, and duration in intermediate- and high-risk patients. Although there was agreement that low-risk patients warrant surveillance, no consensus was reached on the optimal approach for this group.

conclusionsThis is the first study to provide consensus-based guidance incorporating GEP and PRAME status into surveillance recommendations for uveal melanoma, offering a standardized framework to guide clinical practice and future research.

Indexed as

gene-expression profilemetastatic uveal melanoma surveillancePRAMEuveal melanoma

Identifiers

PMID41514630
PMCPMC12784650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.